NCT00544609View on ClinicalTrials.gov

Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

August 31, 2010

Study Completion Date

May 31, 2012

Conditions
Bladder Cancer
Interventions
DRUG

Sorafenib

Level 1: 200 mg/day Level 2: 400mg/day Level 3: 800mg/day

PROCEDURE

Radiotherapy

3th-8th week: sorafenib daily with radiotherapy day 1, 2, 3, 4 and 5, 9th week: sorafenib daily with radiotherapy day 1 and 2

Trial Locations (3)

Unknown

Hospital Clínic i Provincial de Barcelona, Barcelona

Hospital de la Santa Creu i Sant Pau, Barcelona

Institut Català d' Oncología, Barcelona

All Listed Sponsors
lead

Spanish Oncology Genito-Urinary Group

OTHER

NCT00544609 - Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent | Biotech Hunter | Biotech Hunter